BidaskClub upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a buy rating in a research note published on Friday morning.

A number of other equities research analysts have also commented on KPTI. Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a buy rating in a report on Thursday, October 12th. Jefferies Group restated a buy rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Royal Bank of Canada restated a buy rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, October 18th. Robert W. Baird restated a buy rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Finally, Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $17.33.

Shares of Karyopharm Therapeutics (KPTI) opened at $13.06 on Friday. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $14.63.

In other Karyopharm Therapeutics news, insider Sharon Shacham sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $12.50, for a total transaction of $125,000.00. Following the transaction, the insider now directly owns 723,510 shares in the company, valued at approximately $9,043,875. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Christopher Brett Primiano sold 27,042 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $10.28, for a total transaction of $277,991.76. Following the transaction, the senior vice president now owns 11,381 shares in the company, valued at $116,996.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,542 shares of company stock worth $819,692. Corporate insiders own 14.71% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. ProShare Advisors LLC raised its position in shares of Karyopharm Therapeutics by 8.0% in the 2nd quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after acquiring an additional 2,021 shares during the period. Voya Investment Management LLC raised its position in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after acquiring an additional 4,444 shares during the period. Wells Fargo & Company MN raised its position in shares of Karyopharm Therapeutics by 18.8% in the 4th quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock valued at $298,000 after acquiring an additional 4,902 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Karyopharm Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after acquiring an additional 5,586 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Karyopharm Therapeutics by 12.2% in the 2nd quarter. California State Teachers Retirement System now owns 59,844 shares of the company’s stock valued at $542,000 after acquiring an additional 6,500 shares during the period. Institutional investors and hedge funds own 57.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/02/12/karyopharm-therapeutics-kpti-upgraded-to-buy-by-bidaskclub.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.